Clinical Significance of HMGB-1 and TGF-beta Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer

摘要

Lung cancer is associated with poor prognosis. The aim of this study was to evaluate the clinical usefulness of HMGB-1 (high-mobility group protein Bl) and TGF-p (transforming growth factor beta) in patients with advanced non-small cell lung cancer (NSCLC). We studied 45 patients with NSCLC prior to chemotherapy, 23 patients with Besnier-Boeck-Schaumann (BBS) disease (sarcoidosis), and 15 healthy volunteers. HMGB-1 and TGF-p levels were measured in serum and BALF samples using ELISA method. A higher serum HMGB-1 and TGF-p levels were in NSCLC patients compared with the other groups. TGF-p concentration in BALF was significantly higher in NSCLC than in healthy controls (p = 0.047) but lower than in BBS (p = 0.016). Serum HMGB-1 in NSCLC correlated with age and gender while its level in BALF was associated with distant metastasis.